Suppr超能文献

PD-L1 抑制 PD-1Nrp1 Treg 细胞以抑制炎症驱动的结直肠肿瘤发生。

PD-L1 restrains PD-1Nrp1 Treg cells to suppress inflammation-driven colorectal tumorigenesis.

机构信息

Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA 30912, USA; Georgia Cancer Center, Augusta, GA 30912, USA; Charlie Norwood VA Medical Center, Augusta, GA 30904, USA.

Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA 30912, USA.

出版信息

Cell Rep. 2024 Oct 22;43(10):114819. doi: 10.1016/j.celrep.2024.114819. Epub 2024 Oct 3.

Abstract

T cells function not only as an essential component of host cancer immunosurveillance but also as a regulator of colonic inflammation, a process that promotes colorectal cancer. Programmed death-ligand 1 (PD-L1) is a T cell-negative regulator, but its role in regulation of T cell functions in the context of colorectal cancer is unknown. We report that global deletion of Cd274 results in increased colonic inflammation, PD-1 T cells, and inflammation-driven colorectal tumorigenesis in mice. Single-cell RNA sequencing (scRNA-seq) analysis revealed that PD-L1 suppresses subpopulations of programmed cell death protein 1 (PD-1)Nrp1 regulatory T (Treg) cells and interleukin (IL) 6 neutrophils in colorectal tumor. Treg cells produce transforming growth factor (TGF) β to recruit IL6 neutrophils. Neutrophils produce IL6 to inhibit activation of tumor-specific cytotoxic T lymphocytes (CTLs) and primary CTLs. Accordingly, IL6 blockade immunotherapy increases CTL activation and suppresses colon tumor growth in vivo. Our findings determine that PD-L1 restrains PD-1Nrp1TGFβ Treg cells to suppress IL6 neutrophil tumor recruitment to sustain CTL activation to control inflammation-driven colorectal tumorigenesis.

摘要

T 细胞不仅是宿主癌症免疫监视的重要组成部分,也是结肠炎症的调节剂,而结肠炎症会促进结直肠癌的发生。程序性死亡配体 1(PD-L1)是 T 细胞的负调节剂,但它在结直肠癌背景下调节 T 细胞功能的作用尚不清楚。我们报告称,Cd274 的全局缺失会导致小鼠结肠炎症、PD-1 T 细胞增加以及炎症驱动的结直肠肿瘤发生。单细胞 RNA 测序(scRNA-seq)分析显示,PD-L1 抑制结直肠肿瘤中程序性死亡蛋白 1(PD-1)Nrp1 调节性 T(Treg)细胞和白细胞介素(IL)6 中性粒细胞的亚群。Treg 细胞产生转化生长因子(TGF)β来招募 IL6 中性粒细胞。中性粒细胞产生 IL6 来抑制肿瘤特异性细胞毒性 T 淋巴细胞(CTL)和原代 CTL 的激活。因此,IL6 阻断免疫疗法增加 CTL 的激活并抑制体内结肠肿瘤的生长。我们的研究结果确定,PD-L1 抑制 PD-1Nrp1TGFβ Treg 细胞,以抑制 IL6 中性粒细胞肿瘤募集,从而维持 CTL 激活以控制炎症驱动的结直肠肿瘤发生。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d392/11574783/96580d05968c/nihms-2031307-f0002.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验